Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis
Open Access
- 1 August 2002
- Vol. 51 (2) , 265-269
- https://doi.org/10.1136/gut.51.2.265
Abstract
Background: Primary biliary cirrhosis (PBC), a chronic cholestatic liver disease, is frequently associated with severe hypercholesterolaemia but the clinical significance of this finding is unclear. Aims: To characterise changes in serum lipid profile over time and to assess the risk of cardiovascular disease in PBC. Subjects and methods: We studied a cohort of 400 PBC patients for 6.2 years (range 4 months to 24 years) by serial determinations of serum lipid levels and registration of all cardiovascular events. Subjects included in an Italian prospective population based study served as controls. Results: At presentation, 76% of patients had serum cholesterol levels >5.2 mmol/l. Hyperbilirubinaemic patients had higher total cholesterol and lower high density lipoprotein (HDL) cholesterol levels (p<0.001). With time, disease progression was associated with a reduction in total (p<0.001) and HDL (p<0.05) cholesterol. The incidence of cardiovascular events was similar to that of the general population (cerebrovascular events: standardised ratio 1.4; 95% confidence interval 0.5–3.7; coronary events: 2.2; 0.9–4.3). Hypertension was associated with an increased risk of cardiovascular events (3.8; 1.6–8.9). Association with moderate hypercholesterolaemia was of borderline significance (3.8; 0.9–17) whereas severe hypercholesterolaemia was not associated with increased risk (2.4, 0.5–11). Conclusions: In PBC, serum cholesterol levels markedly increase with worsening of cholestasis, and decrease in the late disease stages, despite a severe reduction in biliary secretion. Marked hypercholesterolaemia, typical of severe longstanding cholestasis, is not associated with an excess risk of cardiovascular disease while less advanced patients with moderate hypercholesterolaemia are exposed to an increased cardiovascular risk. Putative protective factors in PBC patients with severe hypercholesterolaemia should be assessed.Keywords
This publication has 28 references indexed in Scilit:
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine*1Hepatology, 1995
- Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics*1, *2Hepatology, 1995
- Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosisHepatology, 1993
- Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosisDigestive Diseases and Sciences, 1993
- Hypercholesterolemia and Atherosclerosis in Primary Biliary Cirrhosis: What Is the Risk?Hepatology, 1992
- High cholestanol and low campesterol-to-sitosterol ratio in serum of patients with primary biliary cirrhosis before liver transplantationHepatology, 1991
- Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level among Men with and without Preexisting Cardiovascular DiseaseNew England Journal of Medicine, 1990
- Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver diseaseGut, 1972
- Mechanisms of Action of Cholestyramine in the Treatment of HypercholesterolemiaCirculation, 1972